Schulman IRB Partners with iMedRIS to Develop IBC Technology

April 5, 2017

Durham, NC & Redlands, CA - Schulman IRB, the industry-leading independent IRB in customer service and technology, announced today that iMedRIS Data Corporation, the fastest growing technology provider for optimizing research compliance and administration software, is developing the technology to power Schulman’s forthcoming institutional biosafety committee (IBC) service.

IBC clients and committee members will work from the same iMedRIS-developed platform, reducing duplicate data entry and the potential for errors while providing users with access to real-time information throughout the review process.

“We looked at a lot of options, and in the end we determined iMedRIS simply offers the best IBC software available,” said Daniel Eisenman, Biosafety Officer at Schulman IRB. “We’re able to easily customize the technology to our clients’ and committee members’ needs, and the system integrates well with our existing systems.”

For research involving human gene transfer (also known as gene therapy research), NIH Guidelines require a thorough risk assessment be performed by an IBC, along with institutional review board (IRB) review, for clinical trials to ensure the risks are identified and adequately mitigated.

Schulman’s forthcoming commercial IBC service will provide an independent option for research sponsors and institutions required to establish IBCs. The service will launch in the spring of 2017.

About Schulman IRB
Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services in clinical quality assurance (CQA) and human research protections (HRP), and its commercial institutional biosafety committee (IBC) service will launch in Spring 2017. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA). For more information, please visit http://www.sairb.com or follow us on Twitter and LinkedIn.

Related Content:

News